Sino Biological Inc. (SHE: 301047), a leading supplier of reagents based in China, has announced a partnership with Canada-based Rapid Novor Inc. Under the terms of the agreement, Sino Biological will market select services from Rapid Novor across multiple Asian markets, including China, Singapore, Thailand, Malaysia, Indonesia, Vietnam, the Philippines, Japan, and South Korea. The collaboration will primarily focus on Rapid Novor’s proprietary de novo REmAb monoclonal antibody (mAb) sequencing services. Financial details of the partnership have not been disclosed.
As a global leader in mammalian cell-based recombinant proteins, antibodies, and related contract research services, Sino Biological’s platform is well-positioned to enhance the reach of Rapid Novor’s advanced mAb sequencing capabilities, creating a synergistic effect between the two companies.- Flcube.com
